image
Coherus BioSciences, Inc. CHRS
Healthcare - Biotechnology - NASDAQ - US
Watchlist
$ 0.8215
5.08 %
$ 95.2 M
Market Cap
3.29
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one CHRS stock under the worst case scenario is HIDDEN Compared to the current market price of 0.822 USD, Coherus BioSciences, Inc. is HIDDEN

CHRS Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one CHRS stock under the base case scenario is HIDDEN Compared to the current market price of 0.822 USD, Coherus BioSciences, Inc. is HIDDEN

CHRS Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one CHRS stock under the best case scenario is HIDDEN Compared to the current market price of 0.822 USD, Coherus BioSciences, Inc. is HIDDEN

CHRS Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart CHRS

image
1M -25%
6M -3%
1Y -152%
3Y -1070%
5Y -1887%
All
$1.8$1.8$1.6$1.6$1.4$1.4$1.2$1.2$1.0$1.0$0.8$0.8$0.6$0.615 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
267 M REVENUE
3.78%
Growth Rates
1Year 3.78%
3Years -6.50%
5Years -5.60%
7Years 108.55%
10Years 23.98%
-112 M OPERATING INCOME
45.05%
Growth Rates
1Year 45.05%
3Years 24.92%
5Years -15.28%
7Years 9.93%
10Years -5.61%
28.5 M NET INCOME
111.98%
Growth Rates
1Year 111.98%
3Years 28.04%
5Years -20.51%
7Years 11.33%
10Years 8.81%
-20.4 M OPERATING CASH FLOW
88.31%
Growth Rates
1Year 88.31%
3Years 18.26%
5Years -11.47%
7Years 27.82%
10Years 1.56%
230 M INVESTING CASH FLOW
59.24%
Growth Rates
1Year 59.24%
3Years 54.17%
5Years 82.22%
7Years 76.87%
10Years 83.83%
-187 M FINANCING CASH FLOW
-268.64%
Growth Rates
1Year -268.64%
3Years -66.36%
5Years -25.33%
7Years -9.64%
10Years -9.04%
54.1 M REVENUE
-23.50%
Growth Rates
1Year 3.78%
3Years -6.50%
5Years -5.60%
7Years 108.55%
10Years 23.98%
-42.2 M OPERATING INCOME
-561.44%
Growth Rates
1Year 45.05%
3Years 24.92%
5Years -15.28%
7Years 9.93%
10Years -5.61%
-50.7 M NET INCOME
100.00%
Growth Rates
1Year 111.98%
3Years 28.04%
5Years -20.51%
7Years 11.33%
10Years 8.81%
28.6 M OPERATING CASH FLOW
146.13%
Growth Rates
1Year 88.31%
3Years 18.26%
5Years -11.47%
7Years 27.82%
10Years 1.56%
-542 K INVESTING CASH FLOW
-122.07%
Growth Rates
1Year 59.24%
3Years 54.17%
5Years 82.22%
7Years 76.87%
10Years 83.83%
231 K FINANCING CASH FLOW
238.32%
Growth Rates
1Year -268.64%
3Years -66.36%
5Years -25.33%
7Years -9.64%
10Years -9.04%
Balance Sheet Coherus BioSciences, Inc.
image
Current Assets 342 M
Cash & Short-Term Investments 126 M
Receivables 122 M
Other Current Assets 93.3 M
Non-Current Assets 107 M
Long-Term Investments 0
PP&E 2.84 M
Other Non-Current Assets 104 M
28.09 %27.27 %20.79 %23.21 %Total Assets$448.5m
Current Liabilities 283 M
Accounts Payable 28.5 M
Short-Term Debt 1.69 M
Other Current Liabilities 253 M
Non-Current Liabilities 298 M
Long-Term Debt 232 M
Other Non-Current Liabilities 66 M
4.90 %43.55 %39.88 %11.37 %Total Liabilities$580.5m
EFFICIENCY
Earnings Waterfall Coherus BioSciences, Inc.
image
Revenue 267 M
Cost Of Revenue 118 M
Gross Profit 149 M
Operating Expenses 261 M
Operating Income -112 M
Other Expenses -140 M
Net Income 28.5 M
300m300m250m250m200m200m150m150m100m100m50m50m00(50m)(50m)(100m)(100m)(150m)(150m)267m(118m)149m(261m)(112m)140m29mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
55.97% GROSS MARGIN
55.97%
Averages
1Year 55.97%
3Years 53.16%
5Years 66.79%
7Years 45.89%
10Years -1053.75%
-41.83% OPERATING MARGIN
-41.83%
Averages
1Year -41.83%
3Years -80.85%
5Years -58.10%
7Years -1913.93%
10Years -2910.65%
10.68% NET MARGIN
10.68%
Averages
1Year 10.68%
3Years -78.86%
5Years -60.52%
7Years -1961.57%
10Years -2984.77%
-21.60% ROE
-21.60%
Averages
1Year -21.60%
3Years 113.03%
5Years 14.54%
7Years 100.08%
10Years 248.47%
6.36% ROA
6.36%
Averages
1Year 6.36%
3Years -33.12%
5Years -25.75%
7Years -45.32%
10Years -64.02%
-66.77% ROIC
-66.77%
Averages
1Year -66.77%
3Years -67.06%
5Years -45.57%
7Years -72.61%
10Years -98.27%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Coherus BioSciences, Inc.
image
150m150m100m100m50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)(300m)(300m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 28.5 M
Depreciation & Amortization 5.28 M
Capital Expenditures 0
Stock-Based Compensation 27.8 M
Change in Working Capital 55.9 M
Others -78.1 M
Free Cash Flow -20.4 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Coherus BioSciences, Inc.
image
Wall Street analysts predict an average 1-year price target for CHRS of $7.5 , with forecasts ranging from a low of $6 to a high of $11 .
CHRS Lowest Price Target Wall Street Target
6 USD 630.37%
CHRS Average Price Target Wall Street Target
7.5 USD 812.96%
CHRS Highest Price Target Wall Street Target
11 USD 1239.01%
Price
Max Price Target
Min Price Target
Average Price Target
121210108866442200May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 7
6. Ownership
Insider Ownership Coherus BioSciences, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS), a commercial-stage innovative oncology company, today announced that an abstract highlighting interim data from its ongoing Phase 1 clinical trial evaluating CHS-114, a selective, cytolytic anti-CCR8 antibody, as monotherapy and in combination with toripalimab in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), has been selected for a poster presentation at the upcoming 2025 AACR Annual Meeting, being held April 25-30, 2025, at McCormick Place Convention Center in Chicago, Illinois. globenewswire.com - 3 weeks ago
Coherus BioSciences, Inc. (CHRS) Q4 2024 Earnings Call Transcript Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q4 2024 Earnings Conference Call March 10, 2025 5:00 PM ET Company Participants Jodi Sievers - Head of IR Denny Lanfear - CEO Paul Reider - CCO Sameer Goregaoker - SVP, Immuno-Oncology Marketing Theresa LaVallee - CDO Rosh Dias - CMO Bryan McMichael - CFO Conference Call Participants Srikripa Devarakonda - Truist Securities Yigal Nochomovitz - Citigroup Colleen Kusy - Baird Michael Nedelcovych - TD Cowen Brian Cheng - JPMorgan Douglas Tsao - H.C. Wainwright Operator Hello everyone and welcome to the Coherus Fourth Quarter Year Ending 2024 Financial Results Conference call. seekingalpha.com - 1 month ago
Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update – Annual net revenue increased 4% to $267.0 million in 2024, despite significant divestitures – – UDENYCA® net revenue increased 62% year-over-year – – LOQTORZI® net revenue increased 29% quarter-over-quarter – globenewswire.com - 1 month ago
Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025 REDWOOD CITY, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its fourth quarter and full year 2024 financial results will be released after market close on Monday, March 10, 2025. Starting at 5:00 p.m. ET on March 10, 2025, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. globenewswire.com - 1 month ago
Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference REDWOOD CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will participate in a fireside chat presentation at the 45th Annual TD Cowen Health Care Conference on Tuesday, March 4, 2025, at 11:50 a.m., Eastern time. A live audio webcast will be accessible through a link posted on the “Events and Presentations” section of the Coherus' investor website:  https://investors.coherus.com/events-presentations . A replay of the presentation will be available on this same website for approximately 90 days. globenewswire.com - 1 month ago
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 - Randomized Phase 2 study initiated evaluating the combination of casdozokitug, toripalimab and bevacizumab in patients with liver cancer - globenewswire.com - 4 months ago
Coherus BioSciences: Shedding Pegfilgrastim To Fuel Ongoing Development Coherus BioSciences focuses on immunotherapy, expanding their PD-1 antibody market, and developing novel treatments for solid tumors, despite maintaining a penny stock valuation. Financially, CHRS holds $97.7 million in cash, $36.6 million in term loans, and $227.9 million in convertible notes, with $70.8 million in net revenues. CHRS is divesting their Udenyca franchise for $483.4 million, with potential milestone payments, following previous sales of Cimerli and Yusimry franchises. seekingalpha.com - 4 months ago
Why Is Coherus BioSciences Stock Trading Higher On Tuesday? On Tuesday, Coherus BioSciences, Inc. CHRS entered into an asset purchase agreement with Intas Pharmaceuticals Ltd for the divestiture of the Udenyca (pegfilgrastim-cbqv) franchise for up to $558.4 million. benzinga.com - 4 months ago
Coherus Management to Participate in the 2024 Citi Global Healthcare Conference REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will participate in the 2024 Citi Global Healthcare Conference, with Dr. Theresa LaVallee, Chief Development Officer, sitting on the Novel Mechanisms in Oncology Panel on December 3, 2024, at 3:15 p.m. ET. globenewswire.com - 4 months ago
Coherus BioSciences, Inc. (CHRS) Q3 2024 Earnings Call Transcript Coherus BioSciences, Inc. (CHRS) Q3 2024 Earnings Call Transcript seekingalpha.com - 5 months ago
Coherus BioSciences (CHRS) Reports Q3 Loss, Tops Revenue Estimates Coherus BioSciences (CHRS) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.27 per share a year ago. zacks.com - 5 months ago
Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update –  Net revenue of $70.8 million in Q3  2024 driven by 30% increase in UDENYCA ®   net revenue, quarter-over-quarter – globenewswire.com - 5 months ago
8. Profile Summary

Coherus BioSciences, Inc. CHRS

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 95.2 M
Dividend Yield 0.00%
Description Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
Contact 333 Twin Dolphin Drive, Redwood City, CA, 94065 https://www.coherus.com
IPO Date Nov. 6, 2014
Employees 228
Officers Dr. Theresa M. Lavallee Ph.D. Chief Development Officer & Chairman of Scientific Advisory Board Mr. Paul Reider Chief Commercial Officer Mr. Scott Saywell Executive Vice President of Corporate Development Mr. Dennis M. Lanfear Chairman, President & Chief Executive Officer Ms. Rebecca Sunshine Chief Human Resources Officer Mr. Bryan J. McMichael Chief Financial Officer Mr. Andy Rittenberg Executive Vice President of General Counsel Mr. Michael Chen Senior Vice President of Commercial Analytics & Trade Ms. Jodi Sievers Vice President of Investor Relations & Corporate Communications Mr. Richard L. Hameister Chief Technical Officer